AnaptysBio, Inc.
ANABAnaptysBio is a clinical-stage biotechnology company dedicated to developing innovative immunology therapeutics for autoimmune and inflammatory diseases.
Earnings
Next report
Aug 5, 2026 (In 3 weeks)Valuation & ratios
Competitors
By market cap
By revenue growth
By net margin
Profile
AnaptysBio is a clinical-stage biotechnology company dedicated to developing innovative immunology therapeutics for autoimmune and inflammatory diseases. The company leverages its proprietary antibody discovery and design platform to create molecules that modulate key immune system nodes. Its value proposition is centered on advancing a wholly owned clinical pipeline while generating significant revenue through financial collaborations and royalty interests in out-licensed programs.
A clinical-stage innovator in immunology with a dual-track strategy of internal drug development and high-value royalty monetization from established pharmaceutical partnerships.
Questions, answered.
- What is AnaptysBio, Inc.'s market cap?
- AnaptysBio, Inc. (ANAB) has a market capitalization of $2.0B and trades on NASDAQ.
- What is AnaptysBio, Inc.'s revenue and profitability?
- AnaptysBio, Inc. generated $232.4M in trailing twelve-month revenue with a net loss of $115.7M, representing a net margin of -49.9%, with free cash flow of $4.4M. These figures are based on the Q1 2026 filing.
- Who are AnaptysBio, Inc.'s competitors?
- AnaptysBio, Inc.'s key competitors include AbbVie Inc., Gilead Sciences, Inc., Eli Lilly and Company, and others. These companies compete in similar markets and product categories.
- Who does AnaptysBio, Inc. partner with?
- AnaptysBio, Inc.'s notable partners include GSK, Vanda Pharmaceuticals Inc., Sagard Healthcare Royalty Partners, LP, and others.
- Where is AnaptysBio, Inc. headquartered?
- AnaptysBio, Inc. is headquartered in United States of America and employs approximately 117 people. It has been publicly traded since 2017.
